The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

12 articles for K Sugita


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.EBI
The University of Tokyo
Discovery of DF-461, a Potent Squalene Synthase Inhibitor.EBI
Daiichi Sankyo
Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERa-selective antagonist.EBI
The University of Tokyo
Discovery of novel tricyclic compounds as squalene synthase inhibitors.EBI
Daiichi Sankyo
Novel selective anti-androgens with a diphenylpentane skeleton.EBI
The University of Tokyo
Discovery of atrop fixed alkoxy-aminobenzhydrol derivatives: novel, highly potent and orally efficacious squalene synthase inhibitors.EBI
Daiichi Sankyo
Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.EBI
The University of Tokyo
Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-relateda-glucosidase inhibitors and liver X receptor antagonists.EBI
The University of Tokyo
Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors.EBI
Daiichi Sankyo
Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists.EBI
The University of Tokyo
Discovery of Novel 11-Membered Templates as Squalene Synthase Inhibitors.EBI
Daiichi Sankyo RD Novare Co., Ltd.
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI
Shionogi